대한한방내과학회지 (The Journal of Internal Korean Medicine)

대한한방내과학회 (The Society of Internal Korean Medicine)
권호 표지
DOI QR코드

DOI QR Code

골수이형성증후군 환자의 한약을 사용한 치험 1례

One Case of Myelodysplastic Syndrome Treated with Herbal Medicine

  • 황조현 (경희대학교 한의과대학 간계내과학교실) ;
  • 김어진 (경희대학교 한의과대학 간계내과학교실) ;
  • 이주영 (경희대학교 한의과대학 간계내과학교실) ;
  • 장은경 (경희대학교 한의과대학 간계내과학교실) ;
  • 이장훈 (경희대학교 한의과대학 간계내과학교실) ;
  • 김영철 (경희대학교 한의과대학 간계내과학교실)
  • Hwang, Cho-Hyun (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Kim, Eujin (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Lee, Juyoung (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Jang, Eungyeong (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Lee, Jang-Hoon (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Kim, Youngchul (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
  • 투고 : 2022.04.10
  • 심사 : 2022.06.30
  • 발행 : 2022.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: The aim of this study was to identify the effects of herbal medicine on the clinical symptoms and abnormal blood tests of a patient with myelodysplastic syndrome. Methods: A 64-year-old woman diagnosed with myelodysplastic syndrome in 2020 was prescribed Bojungikgi-tang-gagambang from January 6, 2022 to June 22, 2022 to reduce bleeding tendency and frequent defecation and to improve laboratory findings, such as platelet count. We observed changes in the symptoms and improvement of laboratory findings after six months of treatment. Results: In this study, approximately six months of treatment with Bojungikgi-tang-gagambang showed considerable improvement in laboratory findings and clinical symptoms, especially frequent defecation, petechiae, and gum bleeding, compared to the baseline parameters of the first visit. Also, no adverse effects, such as liver injury or decreased kidney function, were observed during herbal medicine treatment. Conclusion: This study suggests the availability of herbal medicine as a therapeutic option for managing patients with myelodysplastic syndrome.

키워드

참고문헌

  1. Cazzola M. Myelodysplastic Syndromes. New England Journal of Medicine 2020;383(14):1358-74. https://doi.org/10.1056/nejmra1904794
  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405. https://doi.org/10.1182/blood-2016-03-643544
  3. Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2018, Ministry of Health and Welfare. 2020.
  4. Cheong JW, Min YH. Myelodysplastic Syndrome. Journal of the Korean Medical Association 2006;49(10):897-907. https://doi.org/10.5124/jkma.2006.49.10.897
  5. Cheong JW, Kook H, Bang SM, Lee JH, Joo YD, Kim I, et al. The Clinical Guidelines for Myelodysplastic Syndrome. Blood Research 2007;42(2):71-90.
  6. Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology 2016;2016(1):478-84. https://doi.org/10.1182/asheducation-2016.1.478
  7. Kim JD. A case of myelodysplastic syndrome. Journal of Internal Korean Medicine 1999;20(1):274-9.
  8. Kim JY, Joung JY, Son CG, Cho JH. Well-Managed Myelodysplastic Syndrome Patients Treated with Traditional Korean Medicine; Report of Two Cases. The Journal of Internal Korean Medicine 2016;37(3):539-47.
  9. Joo SH, Bae JH, An SY, Jang EG, Lee JH, Kim YC. A Case Report of a Patient with Myelodysplastic Syndrome Who Has Lower Back Pain. The Journal of Internal Korean Medicine 2018;39(2):230-6. https://doi.org/10.22246/jikm.2018.39.2.230
  10. Duetz C, Cucchi DGJ, Polak TB, Janssen JJWM, Ossenkoppele GJ, Estey EH, et al. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. British Journal of Haematology 2022;196(2):329-35. https://doi.org/10.1111/bjh.17892
  11. Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. The Lancet 2014;383(9936):2239-52. https://doi.org/10.1016/S0140-6736(13)61901-7
  12. Jonas BA, Greenberg PL. MDS prognostic scoring systems - Past, present, and future. Best Practice & Research Clinical Haematology 2015;28(1):3-13. https://doi.org/10.1016/j.beha.2014.11.001
  13. Giagounidis A. Current treatment algorithm for the management of lower-risk MDS. Hematology 2017;2017(1):453-9. https://doi.org/10.1182/asheducation-2017.1.453
  14. Ramos F. Myelodysplastic Syndrome: Riding the Crest of the Wave. Journal of Clinical Medicine 2022;11(6):1616. https://doi.org/10.3390/jcm11061606
  15. Germing U, Kobbe G, Haas R, Gattermann N. Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int 2013;110(46):783-90.
  16. Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, et al. Quality of life and physicians' perception in myelodysplastic syndromes. American Journal of Blood Research 2012;2(2):136-47.
  17. Vicente A, Patel BA, Gutierrez-Rodrigues F, Groarke E, Giudice V, Lotter J, et al. Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. Haematologica 2020;105(12):2785-94. https://doi.org/10.3324/haematol.2020.249995
  18. Gang HI, Jo YS, Sin SH, Chae SY, Ha MH, Jo SG, et al. Stimulation of Macrophage Differentiation by Bu-Zhong-Yi-Qi-Tang Extract. Journal of the Korean Society of Food Science and Nutrition 2005;34(3):330-5. https://doi.org/10.3746/JKFN.2005.34.3.330
  19. Jun JH, Kim JC, Lee JH. Effects of Korean Traditional Medicine on Murine Hematopoiesis. The Journal of Internal Korean Medicine 2001;22(3):156-68.